Evidence map›Paper›PMID 39592501›Full record

ArticleEJNMMI reports2024

[

Cato C Loeff, Willemijn van Gemert, Bastiaan M Privé, Inge M van Oort, Rick Hermsen, Diederik M Somford, James Nagarajah, Linda Heijmen, Marcel J R Janssen

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04239742 (F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer, Comparison With 18F-Fluciclovine), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04239742 naunknown statusnot on this map

F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer, Comparison With 18F-Fluciclovine

TypeinterventionalSponsorRadboud University Medical CenterRan2020 to 2023Enrolled50ConditionsProstate Cancer RecurrentArmsF18-fluciclovine PET/CT, F18-PSMA-1007 PET/CT
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. The Role of Nuclear Medicine in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cato C LoeffDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. cato.loeff@radboudumc.nl.ORCID http://orcid.org/0009-0007-1670-2153
Willemijn van GemertDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Bastiaan M PrivéDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Inge M van OortDepartment of Urology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Rick HermsenDepartment of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Diederik M SomfordDepartment of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
James NagarajahDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Linda HeijmenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Marcel J R JanssenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe objective of this study was to compare the detection rates of [

methodsThis was a prospective, single-center (Radboudumc; Nijmegen, The Netherlands), comparative phase II diagnostic imaging study (NCT04239742). The main inclusion criteria were histologically proven adenocarcinoma of the prostate, BCR after radical treatment with two consecutive (rising) PSA values (0.2-5.0 µg/L). Patients underwent both [

resultsData of fifty patients were included, median age of 71 (IQR: 67-74) years and median PSA value of 0.38 (IQR: 0.30-1.55) µg/L. Detection rates were 68% (34/50) for [

conclusionIn patients with early BCR of prostate cancer after radical surgery or radiotherapy, [

trial registrationClinicalTrials.gov, NCT04239742. Registered 02 January 2020, https://clinicaltrials.gov/study/NCT04239742 .

Indexed as

Biochemical recurrenceFluciclovinePET/CTProstate cancer (PCa)PSMA

Identifiers

PMID39592501
PMCPMC11599519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.